Clodronate treatment reduces serum levels of interleukin-6 soluble receptor in Paget's disease of bone
OBJECTIVE: Interleukin-6 (IL-6) and its soluble receptor (sIL-6R) stimulate osteoclast formation and activity. The primary cell abnormality in Paget's disease of bone (PDB) involves osteoclasts. Pagetic osteoclasts overproduce IL-6 and IL-6 receptor in vitro. In vivo, IL-6 serum levels are very high in the acute phase of PDB. The aim of this study was to evaluate the modification in the serum levels of IL-6, sIL-6R and osteotropic hormones (parathormone, 25OHD3 and 1,25(OH)2D3) as a in long-term response to clodronate treatment in patients with PDB.
METHODS: 16 patients (8 females) with polyostotic PDB were studied. IL-6, sIL-6R and osteotropic hormones serum levels were evaluated in active PDB and after clodronate treatment (300 mg injected intravenously for 5 consecutive days). The sequential changes in total alkaline phosphatase (tALP) serum levels were used to assess the maximal pharmacological response to treatment.
RESULTS: In untreated pagetic patients, mean serum levels of IL-6 (3.20+/-1.18 pg/ml) and sIL-6R (35.02+/-8.33 ng/ml) were significantly increased. Serum osteotropic hormone levels fell within the normal range. Eight weeks after treatment, the maximal pharmacological response to clodronate was associated with a significant reduction of sIL-6R serum levels in all patients, without a significant variation in serum IL-6 and osteotropic hormone levels. Moreover, we observed a correlation between lower sIL-6R serum levels before clodronate therapy and complete remission of PBD, defined as a decrease of tALP serum levels within the normal range.
CONCLUSION: The decrease in serum sIL-6R levels could be one of the molecular mechanisms that play a role in the clinical response to clodronate treatment in PDB.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2002 |
|---|---|
| Erschienen: |
2002 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Clinical and experimental rheumatology - 20(2002), 3 vom: 28. Mai, Seite 359-64 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rendina, D [VerfasserIn] |
|---|
| Themen: |
0813BZ6866 |
|---|
| Anmerkungen: |
Date Completed 10.01.2003 Date Revised 12.01.2017 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM119737892 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM119737892 | ||
| 003 | DE-627 | ||
| 005 | 20231222185410.0 | ||
| 007 | tu | ||
| 008 | 231222s2002 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0399.xml |
| 035 | |a (DE-627)NLM119737892 | ||
| 035 | |a (NLM)12102472 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rendina, D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clodronate treatment reduces serum levels of interleukin-6 soluble receptor in Paget's disease of bone |
| 264 | 1 | |c 2002 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 10.01.2003 | ||
| 500 | |a Date Revised 12.01.2017 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: Interleukin-6 (IL-6) and its soluble receptor (sIL-6R) stimulate osteoclast formation and activity. The primary cell abnormality in Paget's disease of bone (PDB) involves osteoclasts. Pagetic osteoclasts overproduce IL-6 and IL-6 receptor in vitro. In vivo, IL-6 serum levels are very high in the acute phase of PDB. The aim of this study was to evaluate the modification in the serum levels of IL-6, sIL-6R and osteotropic hormones (parathormone, 25OHD3 and 1,25(OH)2D3) as a in long-term response to clodronate treatment in patients with PDB | ||
| 520 | |a METHODS: 16 patients (8 females) with polyostotic PDB were studied. IL-6, sIL-6R and osteotropic hormones serum levels were evaluated in active PDB and after clodronate treatment (300 mg injected intravenously for 5 consecutive days). The sequential changes in total alkaline phosphatase (tALP) serum levels were used to assess the maximal pharmacological response to treatment | ||
| 520 | |a RESULTS: In untreated pagetic patients, mean serum levels of IL-6 (3.20+/-1.18 pg/ml) and sIL-6R (35.02+/-8.33 ng/ml) were significantly increased. Serum osteotropic hormone levels fell within the normal range. Eight weeks after treatment, the maximal pharmacological response to clodronate was associated with a significant reduction of sIL-6R serum levels in all patients, without a significant variation in serum IL-6 and osteotropic hormone levels. Moreover, we observed a correlation between lower sIL-6R serum levels before clodronate therapy and complete remission of PBD, defined as a decrease of tALP serum levels within the normal range | ||
| 520 | |a CONCLUSION: The decrease in serum sIL-6R levels could be one of the molecular mechanisms that play a role in the clinical response to clodronate treatment in PDB | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antimetabolites |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Parathyroid Hormone |2 NLM | |
| 650 | 7 | |a Receptors, Interleukin-6 |2 NLM | |
| 650 | 7 | |a Clodronic Acid |2 NLM | |
| 650 | 7 | |a 0813BZ6866 |2 NLM | |
| 650 | 7 | |a Calcitriol |2 NLM | |
| 650 | 7 | |a FXC9231JVH |2 NLM | |
| 650 | 7 | |a Calcifediol |2 NLM | |
| 650 | 7 | |a P6YZ13C99Q |2 NLM | |
| 700 | 1 | |a Postiglione, L |e verfasserin |4 aut | |
| 700 | 1 | |a Vuotto, P |e verfasserin |4 aut | |
| 700 | 1 | |a Numis, F G |e verfasserin |4 aut | |
| 700 | 1 | |a Di Domenico, G |e verfasserin |4 aut | |
| 700 | 1 | |a Viceconti, R |e verfasserin |4 aut | |
| 700 | 1 | |a Mossetti, G |e verfasserin |4 aut | |
| 700 | 1 | |a Nunziata, V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental rheumatology |d 1989 |g 20(2002), 3 vom: 28. Mai, Seite 359-64 |w (DE-627)NLM012613010 |x 0392-856X |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2002 |g number:3 |g day:28 |g month:05 |g pages:359-64 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2002 |e 3 |b 28 |c 05 |h 359-64 | ||